SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

The crypto $SLAP is trending due to community enthusiasm and its increasing visibility. Community members highlight the project's active team, real-world partnerships, and the meme-ability of the name itself. Many express a bullish sentiment, encouraging others to 'DCA and HODL' and to 'slap the bears.'

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer is trending as the community discusses its potential, particularly around integrations and on-chain development capabilities. Bullish sentiment centers on the project's technology, with some suggesting it's undervalued, while bears cite concerns about price action and tokenomics. Recent upgrades and developer activity are also being closely watched for their impact on adoption.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION is trending as traders discuss recent buybacks and burns, reducing supply, alongside strategic partnerships and significant trading volume on the platform. CZ's recent personal purchase has added to the bullish sentiment, with the community actively speculating on the potential impact. Many are pointing to the project's strong fundamentals and comparing it to competitors.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

AUPH is trending due to recent volatility and community discussion around leadership changes and potential impact of an FDA official's comments. The community is actively discussing the departure of a key figure, patent allowance prospects, and speculation about a potential buyout. Investors are weighing the impact of these events on the company's future prospects.

MUSE

$MUSE is trending as traders discuss its potential for a significant run, citing its low market cap and historical performance, particularly in November. Community members are actively analyzing charts and speculating on potential price targets, while also noting the manipulative nature of the trading. The coin's ties to the NFT20 ecosystem and its governance/reward features are also being highlighted.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is gaining attention as its community, the Wolfpack, rallies around the token and hints at upcoming news. With a strong emphasis on community support and long-term holding, many believe $SAILANA has the potential for significant growth. Discussions frequently reference a potential 1000x increase and draw comparisons to the early days of Shiba Inu.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as investors discuss the EV maker's recent record-high monthly deliveries, with a reported 92.6% increase year-over-year. The community debates whether strong sales figures will translate to profitability and sustained growth, especially amid competition in the Chinese EV market. Community members are closely watching upcoming sales data and production capacity increases for additional positive momentum.

Meet Mochi, the cutest IP on Base – Named after Coinbase CEO Brian Armstrong’s pet cat! Launched before Base’s main-net launch in August 2023, Mochi is a first mover on Base, and is committed to help Base and Coinbase is their mission to bring the next billion users onchain.   Mochi has already received a grant from Coinbase for its efforts to onboard new users and continues to release news and developments that see recognition from Coinbase and Base team members and the wider Base community.   Designed by the artist behind Pudgy Penguins, Antoine Mingo - Mochi’s IP has accrued billions of GIF views globally and gained a large non-crypto native following on social media platforms such as Instagram. Mochi’s mission is to become the most retail friendly IP on Base and position itself for the millions of retail investors being onboarded to Base in 2025 through Coinbase and Base’s efforts.   Join Mochi and the vibrant Mochi community in achieving this mission through weekly initiatives and many exciting developments yet to come and be a part of Base’s journey to becoming the largest onchain economy in crypto!

Mochi

Mochi is trending as community members highlight its potential listing on additional exchanges and its connection to Coinbase through the Base network. Some are drawing comparisons to similar tokens, suggesting it could be the next big mover in the meme coin space. The locked liquidity and the project's utility are also being actively discussed.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

ALVO is trending due to a mix of analyst upgrades and recent news regarding FDA actions. While the company received a Complete Response Letter from the FDA for its AVT05 biosimilar, several analysts have upgraded the stock to a Buy rating, citing the company's growth potential in the biosimilar market. The community is weighing the impact of the CRL against the positive analyst sentiment and the potential of Alvotech's partnership-driven model.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

TVTX is trending due to positive revenue growth driven by its kidney disease treatment, Filspari, and optimism surrounding potential FDA approval for expanded use. Community members are discussing the stock's potential for further gains, citing a large short interest which could fuel a squeeze. Analysts have also weighed in with price target increases based on the company's recent earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Monte Rosa's Stock Gains on Signing $5.7B Licensing Deal With Novartis

GLUE surges 44% after sealing a $5.7B licensing deal with NVS to advance molecular glue degraders for immune diseases.

Monte Rosa Therapeutics (GLUE) Soars 44.1%: Is Further Upside Left in the Stock?

Monte Rosa Therapeutics (GLUE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Monte Rosa Therapeutics jumped 44% on Monday, its strongest session since October 2024, after announcing a second collaboration with Novartis to develop degraders for immune-mediated diseases.&nbsp;The new agreement builds on the companies’ October 2024 global exclusive license deal for Monte Rosa’s VAV1 degraders, including MRT-6160.The latest deal grants Novartis an exclusive license to an undisclosed discovery target, as well as options to license two programs from Monte Rosa’s preclinical immunology pipeline. Monte Rosa will apply its proprietary AI/ML-enabled QuEEN platform to identify and advance degraders, which Novartis will further develop and commercialize.Financial terms include a $120 million upfront payment to Monte Rosa, plus option maintenance payments. The company is also eligible for option exercise fees, and development, regulatory and sales milestones, as well as tiered royalties on global net sales in the high single to low double-digit range.In total, the agreement carries&nbsp;a potential value of up to $5.7 billion, Monte Rosa said. Its publicly disclosed pipeline programs are outside the scope of the collaboration.The company said the deal extends its cash runway and enables faster advancement of both preclinical and clinical immunology and inflammation programs, including wholly owned candidates in Th1, Th2, and Th17-driven autoimmune conditions.&nbsp;CEO Markus Warmuth said the agreement strengthens Monte Rosa’s financial position and relationship with Novartis, while supporting multiple anticipated Phase 2 readouts for MRT-8102, MRT-6160, and MRT-2359.&nbsp;Meanwhile, Fiona Marshall, President of Biomedical Research at Novartis, said the expanded partnership underscores the company’s commitment to targeted protein degradation and the potential of Monte Rosa’s QuEEN platform to generate therapies for immune-mediated diseases with high unmet need.Lazard served as&nbsp;the exclusive financial advisor to Monte Rosa on the agreement.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 370% surge in 24-hour message volume.One user said they were holding their Monte Rosa shares “without any worries,” adding that while the stock did not climb back above $8 on Monday, they expected it to happen by the end of the week, noting they had “seen this play way too many times.”<stembedurl>https://stocktwits.com/Mushichka/message/628771893</stembedurl>Another user highlighted the stock’s 52-week range of $3.50 to $12.40 and suggested they expected shares to move above the 52-week high within the next two weeks, projecting a level between $15 and $18.<stembedurl>https://stocktwits.com/Valuestocktrades/message/628771289</stembedurl><a href="https://stocktwits.com/symbol/GLUE">Monte Rosa’s stock</a> has declined 0.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monte Rosa’s stock (GLUE) has declined 0.1% so far in 2025.  (Photo credit: Getty Images)

Monte Rosa Therapeutics Stock Scores Biggest Gain In Nearly A Year On $5.7B Novartis Deal For Immune-Mediated Diseases

The agreement provides Monte Rosa with $120 million upfront, option payments, and potential milestones, while giving Novartis access to targets from its preclinical immunology pipeline.

Equity

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of +51.61% and +118.09%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q2 Earnings Miss Estimates

Certara (CERT) delivered earnings and revenue surprises of -30.00% and +0.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet

&nbsp;1) Butterfly Network (NYSE: BFLY)<ul><li>Background: Butterfly Network is a digital health company pioneering accessible ultrasound technology through its handheld devices, with a mission to democratize high-quality imaging. The Butterfly iQ series has applications in multiple healthcare settings, enabling diagnostic imaging that is portable, affordable, and accessible.</li><li>The News: Butterfly Network recently partnered with HeartFocus to launch an AI-driven training app for cardiac ultrasound, compatible with Butterfly’s portable iQ devices. The app is designed to help healthcare practitioners acquire essential diagnostic skills, even in remote and underserved areas, boosting Butterfly’s appeal to health professionals globally.</li><li>What It Means: This partnership aligns with Butterfly’s vision of expanding ultrasound accessibility, particularly in resource-limited settings. By combining advanced AI-powered education with Butterfly’s handheld devices, the company positions itself as a leader in mobile diagnostics. As demand for accessible healthcare tech grows, Butterfly Network’s innovation could drive significant adoption and revenue growth.</li><li>Stock Reaction: Shares of BFLY rose 3.8%, with trading volume showing heightened interest following the announcement. Investors appear optimistic that AI integrations will boost device uptake, especially among hospitals and clinics focused on remote care.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_20_24_AM_903272e4bf.png" alt="Screenshot 2024-10-29 at 3.20.24 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;2) Gilat Satellite Networks (NASDAQ: GILT)<ul><li>Background: With over 35 years of experience, Gilat Satellite Networks specializes in satellite-based broadband communication solutions, catering to sectors like government, defense, and enterprise. Known for its high-quality and scalable communication systems, Gilat has a strong global reputation in satellite technology.</li><li>The News: Gilat was awarded a $4 million contract from the U.S. Department of Defense to supply DKET 3421 terminals, versatile communication hubs designed for field deployment. These terminals will enhance mission-critical communications, providing secure, mobile connectivity in challenging environments.</li><li>What It Means: This contract reinforces Gilat’s standing as a trusted defense partner, underscoring the value of its portable satellite solutions in national security contexts. Such government contracts bring stable revenue and validate Gilat’s reliability in high-stakes applications.</li><li>Stock Reaction: GILT shares rose 2.9% on above-average volume, reflecting investor confidence in Gilat’s steady pipeline of government contracts.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_07_AM_975e4948a4.png" alt="Screenshot 2024-10-29 at 3.21.07 AM.png"></li></ul>&nbsp;3) Power Nickel (TSXV: PNPN)<ul><li>Background: Power Nickel, a Canadian junior exploration company, focuses on nickel and other essential metals used in electric vehicle (EV) batteries. Its primary asset, the Nisk property in Quebec, has yielded high-grade nickel and copper, attracting attention within the green tech sector.</li><li>The News: Power Nickel announced promising drill results from the Lion Zone, with intersections showing high concentrations of copper, gold, and palladium. These results enhance the project’s profile, potentially making Power Nickel a key player in sustainable, North American-based battery metals.</li><li>What It Means: With demand for nickel and battery metals on the rise, Power Nickel’s findings position it well to meet the needs of EV manufacturers seeking local, reliable sources. The results are likely to attract both investment and strategic partnerships within the green energy sector.</li><li>Stock Reaction: PNPN shares fell 2.41%, with trading volume up almost 100% from average indicating growing investor enthusiasm for Power Nickel’s expansion potential.</li><li>Stocktwits Insight: <img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_17_AM_62f6fd842f.png" alt="Screenshot 2024-10-29 at 3.21.17 AM.png"></li></ul>&nbsp;4) Genprex (NASDAQ: GNPX)<ul><li>Background: Genprex is a gene therapy company focused on cancer and diabetes treatments. Its flagship product, Reqorsa, aims to restore tumor-suppressor gene function in cancer patients, showing promise in treating resistant forms of lung cancer.</li><li>The News: Genprex presented positive preclinical data on Reqorsa, showcasing potential effectiveness against KRAS-resistant lung cancer, glioblastoma, and mesothelioma. This data, shared at an international symposium, underscores Reqorsa’s potential as a versatile cancer therapy.</li><li>What It Means: These findings reinforce Genprex’s pipeline credibility and could lay the groundwork for future clinical trials. If further studies replicate these results, Genprex may secure institutional investment as the therapy advances toward regulatory milestones.</li><li>Stock Reaction: GNPX shares surged 38.4% on higher-than-normal volume, as the announcement generated interest among investors.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_26_AM_dab873c609.png" alt="Screenshot 2024-10-29 at 3.21.26 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;5) Monte Rosa Therapeutics (NASDAQ: GLUE)<ul><li>Background: Monte Rosa Therapeutics is developing molecular glue degraders, which eliminate disease-causing proteins. This unique drug class has potential applications in autoimmune diseases, inflammation, and other conditions with few existing treatments.</li><li>The News: Monte Rosa announced a $150 million licensing agreement with Novartis to accelerate its VAV1-directed drug development program. The agreement provides Monte Rosa with significant financial backing to pursue its pipeline.</li><li>What It Means: Partnering with Novartis offers Monte Rosa access to substantial resources and validation for its innovative therapy approach. This collaboration could enhance Monte Rosa’s position within the biotech landscape, while boosting investor confidence.</li><li>Stock Reaction: GLUE shares jumped 93.9% as trading volume spiked, 27,000% reflecting market approval of the deal’s long-term growth potential.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_35_AM_fced9c05f9.png" alt="Screenshot 2024-10-29 at 3.21.35 AM.png"></li></ul>&nbsp;6) Atlas Lithium (NASDAQ: ATLX)<ul><li>Background: Atlas Lithium is a lithium exploration and development company working on the Neves project in Brazil’s “Lithium Valley.” With the global shift toward EVs and renewable energy storage, lithium is in high demand for battery production.</li><li>The News: Atlas secured regulatory permits to proceed with lithium extraction and processing at the Neves site. These approvals allow Atlas to develop a processing plant, positioning it to become a lithium supplier in the rapidly expanding EV battery market.</li><li>What It Means: This milestone accelerates Atlas’s journey to become a key player in the lithium supply chain. As EV adoption grows, Atlas’s Neves project may play a crucial role in meeting global lithium demand.</li><li>Stock Reaction: ATLX shares gained 24.7% on increased trading volume (5x), as investors anticipate the project’s potential impact on Atlas’s valuation.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_21_43_AM_6743660382.png" alt="Screenshot 2024-10-29 at 3.21.43 AM.png"></li></ul>&nbsp;7)Procept BioRobotics (NASDAQ: PRCT)<ul><li>Background: Procept BioRobotics specializes in robotic systems for urological procedures. Its AquaBeam Robotic System, a minimally invasive treatment for benign prostatic hyperplasia (BPH), has shown significant market growth.</li><li>The News: Procept reported strong Q3 earnings, driven by increased AquaBeam sales and consumables. The company raised its revenue guidance, signaling robust demand and operational growth.</li><li>What It Means: Procept’s earnings beat highlights its competitive edge in surgical robotics, particularly in the high-demand market for BPH treatment. The raised guidance reflects Procept’s confidence in continued market penetration and long-term revenue potential.</li><li>Stock Reaction: PRCT shares rose 32.3% on significant volume (6x), with investors responding positively to the improved financial outlook.</li><li>Stocktwits Insight:&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_29_at_3_22_05_AM_0dfbb455f8.png" alt="Screenshot 2024-10-29 at 3.22.05 AM.png"></li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tech/all-systems-go-ast-spacemobile-asts-stock-throttles-up-en-route-to-the-stars/">Read now: This Space Stock is up 1,700% From $2 on a Mega Telecom Deal– is This the First of Many Contracts? or is it Headed Back to Penny Land? We Have the Inside Scoop</a>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion on the WVC Facebook Investor Group</a><a target="_blank" rel="noopener noreferrer nofollow" href="http://www.stocktwits.com/wealthyvc">Follow us on Stocktwits</a>&nbsp;&nbsp;Have a Stock Tip or New Story Suggestion? Email us at: Invest@WealthyVC.comDisclaimer: Wealthy VC does not hold a long or short position in any of the stocks, ETFs or cryptocurrencies mentioned in this article.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Small and Micro-Cap Movers: Key News, Market Reactions, and Insider Chatter

Today’s most impactful small-cap stock updates, with exclusive rumors, insights, and analysis from StockTwits

This Biotech Stock Has Doubled Its Value Today Here's Why

Shutterstock

 Key TakeawaysMonte Rosa Therapeutics signed a development and commercialization deal with Novartis that could pay the biotech up to $2.1 billion.The agreement is for Monte...

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Shares of Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>) surged over 130% Monday, marking the stock as the top gainer across U.S. exchanges and reaching levels last seen in July 2022.&nbsp;The surge followed Monte Rosa’s announcement of an exclusive global licensing agreement with Novartis AG (<a class="mention" data-mention="$NVS" data-symbol-id="NVS" href="https://stocktwits.com/symbol/NVS" target="_blank">$NVS</a>) to develop and commercialize its investigational therapies for immune-mediated conditions, particularly MRT-6160.Under this agreement, Novartis gains exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues (MGDs), committing $150 million upfront to Monte Rosa.&nbsp;Additionally, Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, along with tiered royalties on ex-U.S. sales.While Novartis will lead the clinical development beginning with Phase 2, Monte Rosa will complete the current Phase 1 study of MRT-6160, co-fund any Phase 3 clinical development, and share 30% of profits and losses in the U.S. for manufacturing and commercialization.<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1318/314;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/GLUE_sentiment_and_message_volume_Oct_28_4e8f522166.png" alt="GLUE sentiment and message volume Oct 28 .png" width="1318" height="314"></a><figcaption>GLUE sentiment and message volume Oct 28 as of 12:45 p.m. ET | source: Stocktwits</figcaption></figure>Retail investors on Stocktwits reacted with heightened enthusiasm, pushing sentiment on Stocktwits to ‘extremely bullish’ (97/100) levels, the highest in a year.<stembedurl>https://stocktwits.com/MrStocks785/message/590326982</stembedurl>Piper Sandler responded to the news by raising its price target on Monte Rosa shares from $16 to $20 while maintaining an 'Overweight' rating.Before this agreement, Monte Rosa shares were down 13% year-to-date. This recent spike has not only erased those losses but has brought GLUE stock up by 90% for 2024.&nbsp;The collaboration with Novartis is expected to accelerate the advancement of MRT-6160 and could signal substantial growth ahead for Monte Rosa in the biopharma space.For updates and corrections, email&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tsla-faces-key-resistance-level-retail-cautious/cJ2rmkVRJQ">Tesla Stock Ticks Up After Price-Target Hikes, But Retail Wary Of Key Resistance Level</a>

While Novartis will lead the clinical development beginning with Phase 2, Monte Rosa will complete the current Phase 1 study of MRT-6160

Top Gainer Monte Rosa Therapeutics’ Stock Enthralls Retail With Novartis Licensing Deal

Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, along with tiered royalties on ex-U.S. sales.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company, which engages in the developing of precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.37	--	--	N/A
Q2 '25	-$0.38	-$0.36	5.53%	BEAT
Q1 '25	$0.31	--	--	N/A
Q4 '24	-$0.07	-$0.36	-445.72%	MISSED
Q3 '24	-$0.47	-$0.29	38.89%	BEAT

GLUE
Monte Rosa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest GLUE News

GLUEMonte Rosa Therapeutics Inc